Clinical utility of pembrolizumab in the management of orbital recurrence of uveal melanoma: case report
This case demonstrates that pembrolizumab therapy can result in tumor regression of recurrent orbital uveal melanoma and it eventually may be helpful as a neoadjuvant treatment.
Authors
- Francesco Matarazzo (ORCID: https://orcid.org/0000-0002-2614-0234)
- Andrea Elefante (ORCID: https://orcid.org/0000-0002-9093-7096)
- Ciro Costagliola (ORCID: https://orcid.org/0000-0001-8477-6188)
- Maria Paola Laezza (ORCID: https://orcid.org/0000-0002-9442-7376)
- Carmela Barbato
- Adriana Iuliano (ORCID: https://orcid.org/0000-0002-8498-6991)
- Luigi Formisano (ORCID: https://orcid.org/0000-0001-7205-5105)
- Antonella D’Aponte
- Diego Strianese (ORCID: https://orcid.org/0000-0002-6140-7539)
- Maria Laura Passaro (ORCID: https://orcid.org/0009-0009-0215-5624)
Institutions
- University of Molise (IT)
- Federico II University Hospital (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- American Journal of Ophthalmology Case Reports
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1016/j.ajoc.2025.102473
- Primary Topic
- Ocular Oncology and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00